Metastatic Colorectal Cancer
Conditions
Keywords
Cancer Vaccine, AlloStim®, Immunovative, Immunotherapy, Allogeneic Cell Therapy, Cryoablation
Brief summary
This is a personalized anti-cancer vaccine protocol which includes an in-situ (in the body) cancer vaccine step which combines killing a single metastatic tumor lesion by use of cryoablation in order to cause the release of tumor-specific markers to the immune system and then injecting bioengineered allogeneic immune cells (AlloStim) into the lesion as an adjuvant in order to modulate the immune response and educate the immune system to kill other tumor cells where ever they reside in the body.
Detailed description
Colorectal cancer (CRC) ranks as the third most common cancer worldwide. Metastasis is the main reason of death in CRC patients. The current drugs used to treat colorectal cancer provide important treatment options for patients, their limitations including drug resistance, poor efficacy and severe side effects. Development of new therapeutic strategies for KRAS mutant as well as BRAF mutant tumors are therefore highly needed in order to offer a new category of drug (immunotherapy). This study targets the population of mCRC patients that have progressed after two lines of chemotherapy and are not eligible for targeted therapies due to a mutation in KRAS or BRAF. This is a Phase II/III, randomized, open-label, multicenter, controlled, two arm study designed to determine the efficacy in terms of OS and the safety of the InSituVax (AlloStim+ Cryoablation) personalized in-situ anti-cancer vaccine protocol (Treatment Arm) compared with Physician's Choice (PC) of Treatment + Cryoablation (Control Arm) in Metastatic Colorectal Cancer. Subjects are randomized 2:1 into the treatment or control arms.
Interventions
BIOLOGICALAlloStim®
AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
PROCEDUREcryoablation
percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
OTHERPhysician's Choice (PC)
Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
Sponsors
Mirror Biologics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult males and female subjects aged 18 years or older at screening visit 2. Pathological diagnosis of colorectal adenocarcinoma 3. Metastatic disease with at least one lesion in liver * Primary can be intact or resected * Metastatic lesion(s) in liver non-resectable * Extrahepatic disease acceptable 4. KRAS/BRAF mutant disease or KRAS wild type w/previous anti-EGFR treatment 5. At least one liver lesion able to be visualized by ultrasound and determined to be safely assessable for percutaneous cryoablation 6. Previous treatment failure of at 2 previous lines of active systemic chemotherapy for metastatic disease: * Previous chemotherapy must have included one line with oxaliplatin (e.g. FOLFOX) and a previous second line with irinotecan (e.g. FOLFIRI) with or without bevacizumab * If KRAS wild type, at least one anti-EGFR therapy in first or second line * Treatment failure can be due to disease progression or toxicity * Disease progression on 2nd line therapy must be documented radiologically and have occurred during or within 30 days following the last administration of 2nd line chemotherapy 7. ECOG performance score: 0-1 8. Adequate hematological function: Absolute granulocyte count ≥ 1,200/mm3, Platelet count ≥ 100,000/mm3, PT/INR ≤ 1.5 or correctable to \<1.5 at time of interventional procedures, Hemoglobin ≥ 9 g/dL (may be corrected by transfusion) 9. Adequate Organ Function: Creatinine ≤ 1.5 mg/dL, Total bilirubin ≤ 1.5 times ULN, Alkaline phosphatase ≤ 2.5 times ULN, AST or SGOT ≤ 2.5 times ULN, ALT or SGPT≤2.5 times ULN 10. EKG without clinically relevant abnormalities 11. Female subjects: Not pregnant or lactating 12. Subjects with child bearing potential must agree to use adequate contraception 13. Study specific informed consent in the native language of the subject
Exclusion criteria
1. Peritoneal carcinomatosis 2. Moderate or severe ascites requiring medical intervention 3. Prior hepatectomy, ablation or chemoembolization of liver lesion 4. Prior pelvic radiotherapy 5. Clinical or radiological evidence of brain metastasis/leptomeningeal involvement 6. Symptomatic asthma or COPD or any lung condition requiring treatment with steroids 7. Pulmonary lymphangitis or symptomatic pleural effusion (grade ≥ 2) that results in pulmonary dysfunction requiring active treatment or oxygen saturation \<92% on room air 8. Bevacizumab (Avastin®) treatment within 6 weeks of scheduled cryoablation 9. No Regorafenib prior to or during the Study Period 10. Anticoagulant medication for concomitant medical condition (unless can be safely discontinued for invasive cryoablation, biopsy and intratumoral injection procedures) 11. Prior allogeneic bone marrow/stem cell or solid organ transplant 12. Chronic use (\>2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to\>5 mg/day of prednisone) within 30 days of the 1st day of study treatment o Topical corticosteroids are permitted 13. Prior diagnosis of an active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis). Well controlled Type I diabetes allowed. 14. Prior experimental therapy 15. History of blood transfusion reactions 16. Known allergy to bovine products 17. Progressive viral or bacterial infection o All infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on study 18. Cardiac disease of symptomatic nature 19. History of HIV positivity or AIDS 20. Concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless such medications can be discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) prior to cryoablation procedure 21. History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs 22. Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | from randomization within 30 days of accrual to death for any cause followed for up to 2 years from date of randomization | To assess whether cryoablation combined with AlloStim treatment (arm 1) provides an overall survival (OS) advantage when compared to treatment with cryoablation combined with physician's choice (arm 2). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 168 days from randomization | Safety will be evaluated by physical exam, changes in laboratory values and patient reported symptoms |
| Health-Related Quality of Life (HRQoL) | 168 days from randomization | To assess change in HRQoL between treatment arms |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunological Response | 168 days from randomization | blood samples will be evaluated for immunological response and a determination made as to whether immunological response correlates with survival |
| Longitudinal changes in tumor burden | 168 days from randomization | To document the longitudinal changes in tumor burden by Response Evaluation Criteria in Solid Tumors (RECIST) and Immune-Related Response Criteria (irRC) |
Countries
Thailand
Outcome results
None listed